Rapid Decrease in Pruritus With Ruxolitinib Cream for Patients With Atopic Dermatitis: Pooled Results From TRuE-AD1 and TRuE-AD2

Assessment of depth, rapidity of response of abrocitinib and dupilumab in patients with moderate to severe AD in JADE COMPARE using stringent endpoints: atopic dermatitis conference coverage from Clinical Care Options (CCO)

Characterization of skin pain in children with atopic dermatitis: atopic dermatitis conference coverage from Clinical Care Options (CCO)

Analysis of efficacy of oral azoles as a potential treatment for dupilumab facial redness: atopic dermatitis conference coverage from Clinical Care Options (CCO)

Interactive on-demand CCO Webcast featuring expert discussion on how new and emerging data in the management of atopic dermatitis will affect clinical practice

Andrew F. Alexis, MD, MPH Jonathan Silverberg, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Released: November 5, 2020 Expired: November 4, 2021

Introduction

Management of Moderate to Severe Atopic Dermatitis With Current Agents

Investigational Agents for the Treatment of Atopic Dermatitis

Targeted Monoclonal Antibodies for AD: Beyond Dupilumab

Questions and Answers